covid
Buscar en
Gaceta Médica de Bilbao
Toda la web
Inicio Gaceta Médica de Bilbao Hipertensión arterial y diabetes. Avances terapéuticos
Información de la revista
Vol. 99. Núm. 3.
Páginas 73-80 (enero 2002)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 99. Núm. 3.
Páginas 73-80 (enero 2002)
Acceso a texto completo
Hipertensión arterial y diabetes. Avances terapéuticos
Arterial hypertension and diabetes. Therapeutic advances
Visitas
2771
V. Giner,*, J. Redón*, J. Ocharan**, B. Aurrekoetxea***
* Hospital Clínico de Valencia. Valencia.
** Hospital de Galdakao. Bizkaia.
*** Hospital de Txagorritxu. Vitoria-Gasteiz
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Resumen

La importancia de la asociación entre la hipertensión arterial (HTA) y la diabetes mellitus es evidente y por ello, se realiza una revisión de la literatura biomédica de dicho tema. Los grandes ensayos clínicos demuestran el beneficio derivado del estricto control tensional en la diabetes mellitus. El efecto del control de las cifras tensionales sobre la patología microvascular es comparable al obtenido con el control glucémico estricto, y superior a éste al considerar la morbilidad macrovascular. Los beneficios derivados del control tensional estricto y la reducción de los valores de presión arterial óoptima a 130/85 mmHg son analizados en este manuscrito. Para finalizar, se revisan los diferentes fármacos antihipertensivos y las nuevas perspectivas en el tratamiento del hipertensivo diabético.

Palabras clave:
Hipertensión arterial
Diabetes mellitus
Valor de presión arterial óptimo
Tratamiento
Fármacos
Summary

The importance of the association between the arterial hypertension and the diabetes mellitus is evident, and for that reason, a revision of the biomedical Literature of this subject is made. The great clinical tests demonstrate to the benefit derived from the strict tensional controls in the diabetes mellitus. The effect of the control of the tensional numbers on the microvascular pathology is comparable to obtained with the control glucemic strict, and superior to this one when considering the macrovascular morbidity. The benefits derived from strict the tensional control and the reduction of the values of optimal arterial pressure to 130-85 mmHg are analyzed in this manuscript. In order to finalize, the different antihypertensive drugs and the new perspective in the treatment from the diabetic hypertensive patient are reviewed.

Key words:
Arterial hypertension
Diabetes mellitus
Optimal arterial pressure
Treatment
Drugs
Laburpena

Hipertentsio arterialaren (HTA) eta diabetes mellitusaren arteko loturaren garrantzia begien bistakoa denez, gaiaren inguruko literatura biomedikoaren berrikuspena etengabekoa da. Saiakuntza klinikoek agerian utzi dute tentsioa zorrotz kontrolatzeak diabetes mellitusaren tratamenduan duen onura. Tentsioa kontrolatzeak patologia mikrobaskularrean eragiten duen efektua kontrol gluzemiko zorrotzarekin lortzen denarekin aldera daiteke, eta azken hori baino handiagoa da erikortasun makrobaskularra kontsideratuz gero. Idatzi honetan, tentsioa zorrotz kontrolatzeak eta tentsio arterial optimoaren balioak 130/85 mmHg-ra murrizteak eragiten dituzten onurak azalduko ditugu. Halaber, botika anti hipertentsiboak eta hipertentsio diabetikoaren tratamenduaren inguruko berrikuntzak aztertuko ditugu.

Hitz gakoak:
Hipertentsio arteriala
Diabetes mellitusa
Tentsio arterial optimoaren balioa
Tratamendua
Botikak
El Texto completo está disponible en PDF
Referencias bibliográficas
[1.]
Redón J., Giner V..
Protección cardiovascular en el paciente con diabetes mellitus tipo 2. Avances en Hipertensión Arterial. Medicina Clínica Monografías.
Medicina Clínica (Barc), pp. 39-45
[2.]
Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M..
Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction.
N Engl J Med, 339 (1998), pp. 229-234
[3.]
Stamler J., Vaccaro O., Neaton J.D., Wentworth D..
Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial.
Diabetes Care, 16 (1993), pp. 434-444
[4.]
Garber A.J..
Effective treatment of hypertension in patients with diabetes mellitus.
Clin Cardiol, 15 (1992), pp. 715-719
[5.]
Collado-Mesa F., Colhoun H.M., Stevens L.K., Boavida J., Ferriss J.B., Karamanos B., Kempler P., Michel G., Roglic G., Fuller J.H..
Prevalence and management of hypertension in type 1 diabetes mellitus in Europe: the EURODIAB Complications Study.
Diabet Med, 16 (1999), pp. 41-48
[6.]
Hypertension in Diabetes Study Group.
HDS 1: Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardio-vascular and diabetic complications.
J Hypertens, 11 (1993), pp. 309-317
[7.]
Epstein M..
Diabetes and hypertension: the bad companions.
J Hypertens, 15 (1997), pp. S55-S62
[8.]
Chatuverdi N., Sjolie A.K., Stephenson J.M., Abrahamian H., Keikes M., Castellarin A., et al.
Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes.
Lancet, 351 (1998), pp. 28-31
[9.]
The EUCLID Study Group.
Randomised plavebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria.
Lancet, 349 (1997), pp. 28-31
[10.]
Forrest K.Y.Z., Maser R.E., Pambianco G., Becker D.J., Orchard T.J..
Hypertension as a risk factor for diabetic neuropathy. A Prospective study.
Diabetes, 46 (1997), pp. 665-670
[11.]
Ritz E., Keller C., Bergis K., Strojek K..
Pathogenesis and course of renal disease in IDDM/NIDDM. Differences and similarities.
Am J Hypertens, 10 (1997), pp. 202S-207S
[12.]
Rocchini A.P., Katch V., Kresilis D., et al.
Insulin and renal sodium retention in obese adolescents.
Hypertension, 14 (1989), pp. 367-374
[13.]
Ferrannini E., Buzzigoli G., Bonadonna, et al.
Insulin resistance in essential hypertension.
N Engl J Med, 317 (1987), pp. 350-357
[14.]
Levy J., Zemel M.B., Sowers J.R..
Role of cellular calcium metabolism in abnormalities in glucose matabolism and diabetic hypertension.
Am J Med, 87 (1989), pp. 7-16
[15.]
Canessa M., Falkner B., Hulman S..
Red blood cell Na+/H+ exchanger (EXC) activity is elevated in young hypertensive blacks.
Hypertension, 18 (1991), pp. 378
[16.]
Epstein M., Sowers J.R..
Diabetes mellitus and hypertension.
Hypertension, 19 (1992), pp. 403-418
[17.]
Lorenzi M., Cagliero E., Toledo S..
Glucose toxicity for human endothelial cells in culture: Delayed replication, disturbed cell cycle and accelerated death.
Diabetes, 34 (1985), pp. 621-627
[18.]
Landin K., Tengborn L., Smith U..
Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension is related to metabolic risk factors for cardiovascular disease.
J Intern Med, 227 (1990), pp. 273-278
[19.]
Oppenheimer M.J., Sundquist K., Bierman E.L..
Down-regulation of high density lipoprotein receptor in human fibroblasts by insulin and IGF-1.
Diabetes, 38 (1989), pp. 117-122
[20.]
King G.L., Goodman A.D., Buzney S., Moses A., Kahn C.R..
Receptors and growth-promoting effects of insulin and insulin-like growth factors on cells from bovine retinal capillaries and aorta.
J Clin Invest, 75 (1985), pp. 1028-1036
[21.]
The Hypertension in Diabetes Study Group (HDS).
Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications.
J Hypertens, 11 (1993), pp. 309-317
[22.]
Mogensen C.E..
Combined high blood pressure and glucose in type 2 diabetes: double jeopardy.
Lancet, 317 (1998), pp. 693-694
[23.]
The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
Arch Intern Med, 157 (1997), pp. 2413-2416
[24.]
Hypertension in diabetes Study IV.
Therapeutic requirements to maintain tigh blood pressure control.
Diabetologia, 34 (1991), pp. 877-890
[25.]
UK Prospective Diabetes Study Group.
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.
BMJ, 317 (1998), pp. 703-713
[26.]
UK Prospective Diabetes Study Group.
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39.
BMJ, 317 (1998), pp. 713-720
[27.]
Hansson L., Zanchetti A., Carruthers S.G., Dahlöf B., Elmfeldt D., Julius S., Ménard J., Rahn K.H., Wedel H., Westerling S., for the HOT Study Group.
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial.
Lancet, 351 (1998), pp. 1755-1762
[28.]
Systolic Hypertension in the Elderly Program Cooperative Research Group.
Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension.
JAMA, 276 (1996), pp. 1886-1892
[29.]
Systolic Hypertension in the Elderly Program Cooperative Research Group.
Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension.
JAMA, 276 (1996), pp. 1886-1892
[30.]
Staessen J., Fagard R., Thijs L., Celis H., Arabidze G.G., Birkenhäger W.H., et al.
Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension.
Lancet, 350 (1997), pp. 757-764
[31.]
Tuomilehto J., Rastenyte D., Birkenhäger W.H., Thijs L., Antikainen R., Bulpitt C.J., et al.
Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension.
N Engl J Med, 340 (1999), pp. 677-684
[32.]
The Heart Outcomes Prevention Evaluation Study Investigators.
Effects of an angiotensinconverting-enzyme inhibitor, Ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients.
N Engl J Med, 342 (2000), pp. 145-153
[33.]
The Heart Outcomes Prevention Evaluation Study Investigators.
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and the Micro-HOPE substudy.
Lancet, 355 (2000), pp. 253-258
[34.]
Hansson L., Lindholm L.H., Ekbom T., Dahölf B., Lanke J., Scherstén B., et al.
Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.
Lancet, 354 (1999), pp. 1751-1756
[35.]
Brown M.J., Palmer C.R., Castaigne A., de Leeuw P.W., Mancia G., Rosenthal T., Ruilope L.M..
Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Interventions as a goal in Hypertension Treatment (INSIGHT).
[36.]
Hansson L., Hedner T., Lund-Johansen P., Kjeldsen S.E., Lindholm L.H., Syvertsen J.O., et al.
Randomised trial of effects of calcium antagonists compared with diuretics ans beta-blockeres on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study.
Lancet, 356 (2000), pp. 359-365
[37.]
Davis B.R., Cutler J.A., Gordon D.J., Furberg C.D., Wright J.T., Cushman W.C..
Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack trial (ALLHAT).
J Hypertens, 9 (1996), pp. 342-360
[38.]
Kostis J.B., Berge K.G., Davis B.R., Hawkins M., Probstfield J..
Effect of atenolol and reserpine on selected events in the Systolic Hypertension in the Elderly Program (SHEP).
Am J Hypertens, 8 (1995), pp. 1147-1153
[39.]
Abernethy D.R., Schwartz J.B..
Calcium-antagonist drugs.
N Engl J Med, 341 (1999), pp. 1447-1457
[40.]
UK Prospective Diabetes Study Group.
Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40.
BMJ, 317 (1998), pp. 720-726
[41.]
Blood Pressure Lowering Treatment Trialists Collaboration.
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of propectively designed overviews of randomized trials.
Lancet, 355 (2000), pp. 1955-1964
[42.]
Rodby R.A., Rohde R.D., Clarke W.R., Hunsicker L.G., Anzalone D.A., Atkins R.C., et al.
The Irbesartan type II diabeteic nephropathy trial: study design and baseline patient characteristics.
For the Collaborative Study Group. Nephrol Dial Trnasplant, 15 (2000), pp. 487-497
[43.]
Parulkar A.A., Pendergrass M.L., Granda-Ayala R., Lee T.R., Fonseca V..
Nonhypoglycemic effects of thiazolidinediones.
Ann Intern Med, 134 (2001), pp. 61-71
Copyright © 2002. Academia de Ciencias Médicas de Bilbao
Opciones de artículo